Citations

Clear

114 citation(s) found for "Maria, Lapid".

ECT‐AD: Baseline Demographics of a Novel Therapeutic Intervention for Severe Agitation and Aggression in Dementia
Forester, Brent P. , Merrill, Julia G. , Hermida, Adriana P., Nykamp, Louis, Mattingly, Jefferson, Seiner, Steve, Petrides, Georgios, Lapid, Maria I. , Mueller, Martina , Patrick, Regan

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S4 | Pages: No page available

10.1002/alz.085641 Get It

AbstractBackgroundEffect and Safety of Electroconvulsive Therapy plus Usual Care for the Acute Management of Severe Agitation in Dementia (ECT‐AD) is a multi‐site NIA‐funded FDA‐regulated pioneering clinical trial to investigate the effectiveness of electroconvulsive therapy (ECT) in treating severe and treatment‐refractory agitation and aggression among individuals with advanced dementia, a condition that has a profound negative impact on patient quality of life and caregiver burden. Here we present baseline demographics of the patient population in this ongoing trial.MethodTo date we have enrolled 18 participants, with a mean age of 74.1 years, where majority are male (61.1%). The racial composition is predominantly White (94.4%), with Asian representation (5.6%, 1/18), and with 11.1% (2/18) identifying as Hispanic or Latino. Dementia subtypes in our cohort include Alzheimer’s disease (AD, 77.8%), vascular dementia (VaD, 16.7%, 3/18), and frontotemporal dementia (FTD, 5.6%, 1/18).ResultBaseline assessments reveal severe cognitive and functional impairment, as indicated by a mean Mini‐Mental State Examination (MMSE) score of 4.0, Barthel Index (BI) score of 52.2, and SIB‐8 score of 2.9, all consistent with advanced stages of dementia. High mean total scores on the Cohen‐Mansfield Agitation Inventory (CMAI, 75.8), Neuropsychiatric Inventory (NPI) agitation (15.1) and aggression (9.2) scales, and Pittsburgh Agitation Scale (PAS, 7.8), reflect the severe levels of agitation and aggression in our participants.ConclusionThese baseline demographic and clinical data underscore the profound impact of advanced dementia, highlighting the need for innovative treatment approaches like ECT. The ECT‐AD trial offers a critical step towards understanding and improving the management of agitation in dementia, with implications that could enhance current clinical care practices.
Longitudinal Neuropsychiatric Symptom Trajectories in Frontotemporal Dementia: From Presymptomatic to Symptomatic Conversion
Scott, Imogene, Chatterjee, Atri , Mackenzie, Ian R. , Huey, Edward D. , Kantarci, Kejal, Rankin, Katherine P. , Rosen, Howard J. , Boxer, Adam L., Lee, Hyun Woo , Lapid, Maria I. , Tartaglia, Maria Carmela , Kantarci, Kejal , Boeve, Bradley F. , Boxer, Adam L. , Hsiung, Ging‐Yuek Robin

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.090036 Get It

AbstractBackgroundFrontotemporal dementia (FTD) presents with heterogeneous neuropsychiatric symptoms (NPS). These symptoms often begin prior to the onset of FTD, and progress throughout the prodromal stages of FTD. Particularly, familial FTD due to autosomal dominant genetic mutations might display mutation‐specific NPS profiles. We hypothesized distinct NPS trajectories for chromosome 9 open reading frame 72 (C9orf72), progranulin (GRN), and microtubule‐associated protein tau (MAPT) mutation carriers during their transition from presymptomatic to symptomatic stages of FTD.MethodIn this study, we analyzed N = 1662 participants from the ARTFL‐LEFFTDS Longitudinal FTLD (ALLFTD) Study, with 342 C9orf72, 148 GRN, 168 MAPT mutation carriers, and 1004 noncarriers. We used the CDR plus NACC FTLD global scores to define the conversion status, and stratified participants into four stages of progression: 1) Presymptomatic (CDR = 0 throughout the follow‐up), 2) Early conversion (began with CDR = 0, then increased to 0.5), 3) Advanced conversion (began with CDR = 0.5, then increased to 1.0 or above), and 4) Symptomatic (CDR>1.0 throughout). Over up to seven visits, the Neuropsychiatric Inventory Questionnaire (NPI‐Q) assessed changes in NPS. We analyzed total NPI‐Q score trajectories using a generalized linear mixed‐effects model, adjusting for age and baseline NPI‐Q scores.ResultOur findings showed similar NPS trajectories among carriers and noncarriers during presymptomatic stages. However, in the early conversion stage, C9orf72 and GRN carriers exhibited significantly higher NPI‐Q score increases compared to MAPT carriers, primarily in the psychosis and hyperactivity domains. In the advanced and symptomatic stages, the rate of increase in NPS was not significantly different across groups.ConclusionThis study suggests that people with familial FTD, particularly those predicted to have underlying TDP‐43 pathology, may experience more severe neuropsychiatric symptoms like psychosis or hyperactivity as they progress from presymptomatic to prodromal phases. This trajectory appears distinct from those with tau pathology or sporadic FTD. Further studies are warranted to understand these unique progression patterns and their implications for FTD management.
Evaluating Repetitive Transcranial Magnetic Stimulation for Neuropsychiatric Symptoms in Long COVID
Kung, Simon , Bock, Jonathan, Hurt, Ryan T. , Bock, Jonathan, Ganesh, Ravindra , Lapid, Maria I.

Mayo Clinic

The Journal of ECT | November 12, 2024 | Volume: 41 | Issue: 2 | Pages: 101-104

10.1097/yct.0000000000001072 | PMID 39531278 Get It

Objective To describe the immediate clinical outcomes of repetitive transcranial magnetic stimulation (rTMS) in treating long COVID symptoms. Long COVID currently impacts approximately 5.3% of US adults, presenting with persistent fatigue, depression, anxiety, cognitive impairments, and social function decline. Repetitive transcranial magnetic stimulation targeting the left dorsolateral prefrontal cortex has improved these symptoms in some studies. Methods Five patients (ages 52–63 years, 3 female patients) underwent accelerated rTMS using intermittent theta burst stimulation (600 pulses over 3 minutes 20 seconds, 80%–120% of resting motor threshold) to the left dorsolateral prefrontal cortex. The treatment consisted of twice-daily sessions over 20–30 treatments. Outcomes were measured using the Patient-Reported Outcomes Measurement and Information System (PROMIS) questionnaires, assessing fatigue, depression, anxiety, cognitive function, and social function at baseline and immediately posttreatment. Results One patient discontinued immediately due to intolerable scalp pain. Posttreatment PROMIS scores showed the following: fatigue decreased from 74.5 to 61.8, depression from 60.3 to 51.5, and anxiety from 62.0 to 54.0. Scores increased for cognitive (26.8 to 32.3) and social (31.0 to 32.5) function. These changes, although not statistically significant, indicate a trend toward symptom reduction. Subjectively, 3 of 4 patients who completed the rTMS course reported improvements. Conclusion This case series suggests that rTMS may offer symptomatic relief in long COVID patients. Although the observed improvements in PROMIS were not statistically significant, even minimal improvements are clinically significant for patients enduring prolonged suffering. These preliminary findings are encouraging and underscore the need for further research with larger cohorts to validate the efficacy of rTMS in long COVID symptom relief.
Self-Rated ECT Outcomes in Patients With Depression
Berger, S , Kung, Simon , Berger, Shane R , Lapid, Maria I.

Mayo Clinic

The Journal of ECT | November 12, 2024 | Volume: 41 | Issue: 3 | Pages: 183-187

10.1097/yct.0000000000001081 | PMID 39531338 Get It

Objectives Electroconvulsive therapy (ECT) is considered to be the most effective treatment for severe depression. This study investigated recent ECT outcomes for depression at a large tertiary center, which also provides community care. Methods Data were obtained from Mayo Clinic Rochester patients ages 18 and older who received an acute course of ECT between August 1, 2017 and April 30, 2024. Patients were included if there was a depressive disorder diagnosis (unipolar or bipolar) and a self-rated Patient Health Questionnaire-9 (PHQ-9) within 10 days of the start and end of the acute course. Patients were excluded if the starting PHQ-9 score was less than 10. The age, sex, number of acute course treatments, stimulus electrode lead placement, and PHQ-9 scores were collected. Response (PHQ-9 improvement ≥50%) and remission (PHQ-9 < 5) rates were calculated. Linear and logistic regressions were performed to investigate predictors of response and remission. Results Of 1206 patients identified, 408 met final inclusion and exclusion criteria. The response rate was 80.4%, and remission rate was 52.7%. Logistic regression for response showed no significant predictors; the P value for age just missed statistical significance (odds ratio, 1.0152; 95% confidence interval, 0.9991–1.0316; P = 0.0641). Logistic regression for remission showed only a lower baseline PHQ-9 score (odds ratio, 0.9465; 95% confidence interval, 0.9049–0.9891; P = 0.0152) as a significant predictor. Conclusions Our results affirmed the high efficacy of ECT in severe depression. No other established treatment for depression can report a response rate as high as 80% in a naturalistic study. This study supports the continued relevance and place of ECT for severe depression.
Navigating Gender Identity and Dementia in Transgender Older Adults: Ethical Challenges and Patient-Centered Care
Joyce, Jeremiah B. , Aphisitphinyo, Sirinapa , Pagali, Sandeep R. , Lapid, Maria I. , Pagali, Sandeep , Lapid, Maria I. , Joyce, Jeremiah , Gentry, Melanie T

Mayo Clinic

Clinical Gerontologist | September 6, 2024 | Volume: 48 | Issue: 2 | Pages: 354-359

10.1080/07317115.2024.2399575 | PMID 39238114 Get It

A Delphi Approach to Define Lucid Episodes in People Living With Dementia
Bangerter, Lauren R. , Kim, Kyungmin , Finnie, Dawn M., Gaugler, Joseph E. , Biggar, Virginia , Frangiosa, Theresa, Gaugler, Joseph E , Griffin, Joan M. , Lapid, Maria I. , Kim, Kyungmin

Mayo Clinic

Alzheimer Disease & Associated Disorders | May 17, 2024 | Volume: 38 | Issue: 2 | Pages: 147-151

10.1097/wad.0000000000000621 | PMID 38757575 Get It

Purpose: Lucid episodes (LEs: unexpected episodes of spontaneous, meaningful, and relevant communication or behavior) in Alzheimer disease and related dementias are a new area of scientific inquiry that lacks clinical consensus and require more conceptual attention. Methods: We aimed to measure consensus from an expert group on: (1) potential medical or clinical explanations for LEs; (2) necessary medical and clinical context to LEs; and (3) interpretation of LEs. Patients: We convened 13 experts from different disciplines (neurology, psychiatry, psychology, pharmacy, palliative care, hospice, nursing, social work, primary care, geriatrics, and professional home caregivers) to identify elements of LEs. Results: Experts provided a range of opinions on medical and clinical explanations and questions to understand LEs. Consensus on LEs when presented with clinical vignettes was not reached. Panelists highlighted key medical and contextual factors needed to make a definitive judgement about LEs. Conclusion: There is variability in how LEs are interpreted by clinical experts, which complicates the identification of LEs in Alzheimer disease and related dementias.
Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration
Staffaroni, Adam M. , Clark, Annie L , Taylor, Jack C. , Heuer, Hilary W. , Wise, Amy B. , Dhanam, Sreya , Wolf, Amy , Manoochehri, Masood , Forsberg, Leah K. , Mester, Carly , Rankin, Katherine P. , Clark, David , Darby, R. Ryan , Domoto‐Reilly, Kimiko , Fields, Julie A. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Huey, Edward D. , Masdeu, Joseph C. , Massimo, Lauren , Mendez, Mario F. , Miyagawa, Toji , Pascual, Belén , Pressman, Peter , Ramos, Eliana Marisa , Rascovsky, Katya, Roberson, Erik D. , Wong, Bonnie , Kornak, John , Kremers, Walter K. , Hassenstab, Jason , Kramer, Joel H. , Rosen, Howard J. , Boxer, Adam L. , Apostolova, Liana G. , Barmada, Sami J. , Brushaber, Danielle , Day, Gregg S, Dickerson, Bradford, Faber, Kelley, Fagan, Anne M. , Foroud, Tatiana M., Gavrilova, Ralitza H. , Graff‐Radford, Jonathan , Grant, Ian , Hall, Matthew , Hales, Chadwick M. , Huang, Eric J. , Johnson, Noah R. , Kolander, Tyler, Kwan, Justin , Lago, Argentina Lario , Lavigne, Shannon B., Lee, Suzee, Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , McGinnis, Scott, Molden, Joie, Naasan, Georges , Onyike, Chiadi U. , Petrucelli, Leonard , Rademakers, Rosa , Rao, Meghana , Rhoads, Kristoffer , Ritter, Aaron, Rogalskı, Emily , Savica, Rodolfo , Sullivan, Anne C. , Syrjanen, Jeremy M., Weıntraub, Sandra , Wint, Dylan , Yokoyoma, Jennifer, Roberson, Erik , Pascual, Belen , Hassenstab, Jason , Kremers, Walter K , Domoto-Reilly, Kimiko , Barmada, Sami , Sanderson‐Cimino, Mark , Cobigo, Yann , Appleby, Brian S. , Bayram, Ece , Bozoki, Andrea C , Galasko, Douglas , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Jones, David T. , Lapid, Maria I. , Litvan, Irene , Masdeu, Joseph C , Ramanan, Vijay K. , Tartaglia, Maria Carmela , Miller, Bruce L. , Boeve, Bradley F. , Botha, Hugo , Day, Gregg S, Dickson, Dennis W. , Elahi, Fanny M. , Fong, Jamie , Gendron, Tania F. , Goldman, Jill , Honig, Lawrence S. , Irwin, David J. , Johnson, Noah, Kantarci, Kejal , Knopman, David S. , Léger, Gabriel C. , McMillan, Corey T. , Pantelyat, Alexander , Paolillo, Emily W. , Paulson, Henry L. , Rexach, Jessica E. , Rojas, Julio C. , Seeley, William W. , Snyder, Allison , Sullivan, Anne C., Tipton, Philip W. , Vandebergh, Marijne , Toga, Arthur W. , VandeVrede, Lawren , Wszołek, Zbigniew K.

Mayo Clinic

JAMA Network Open | April 1, 2024 | Volume: 7 | Issue: 4 | Pages: e244266

10.1001/jamanetworkopen.2024.4266 | PMID 38558141 Get It

ImportanceFrontotemporal lobar degeneration (FTLD) is relatively rare, behavioral and motor symptoms increase travel burden, and standard neuropsychological tests are not sensitive to early-stage disease. Remote smartphone-based cognitive assessments could mitigate these barriers to trial recruitment and success, but no such tools are validated for FTLD.ObjectiveTo evaluate the reliability and validity of smartphone-based cognitive measures for remote FTLD evaluations.Design, Setting, and ParticipantsIn this cohort study conducted from January 10, 2019, to July 31, 2023, controls and participants with FTLD performed smartphone application (app)–based executive functioning tasks and an associative memory task 3 times over 2 weeks. Observational research participants were enrolled through 18 centers of a North American FTLD research consortium (ALLFTD) and were asked to complete the tests remotely using their own smartphones. Of 1163 eligible individuals (enrolled in parent studies), 360 were enrolled in the present study; 364 refused and 439 were excluded. Participants were divided into discovery (n = 258) and validation (n = 102) cohorts. Among 329 participants with data available on disease stage, 195 were asymptomatic or had preclinical FTLD (59.3%), 66 had prodromal FTLD (20.1%), and 68 had symptomatic FTLD (20.7%) with a range of clinical syndromes.ExposureParticipants completed standard in-clinic measures and remotely administered ALLFTD mobile app (app) smartphone tests.Main Outcomes and MeasuresInternal consistency, test-retest reliability, association of smartphone tests with criterion standard clinical measures, and diagnostic accuracy.ResultsIn the 360 participants (mean [SD] age, 54.0 [15.4] years; 209 [58.1%] women), smartphone tests showed moderate-to-excellent reliability (intraclass correlation coefficients, 0.77-0.95). Validity was supported by association of smartphones tests with disease severity (r range, 0.38-0.59), criterion-standard neuropsychological tests (r range, 0.40-0.66), and brain volume (standardized β range, 0.34-0.50). Smartphone tests accurately differentiated individuals with dementia from controls (area under the curve [AUC], 0.93 [95% CI, 0.90-0.96]) and were more sensitive to early symptoms (AUC, 0.82 [95% CI, 0.76-0.88]) than the Montreal Cognitive Assessment (AUC, 0.68 [95% CI, 0.59-0.78]) (z of comparison, −2.49 [95% CI, −0.19 to −0.02]; P = .01). Reliability and validity findings were highly similar in the discovery and validation cohorts. Preclinical participants who carried pathogenic variants performed significantly worse than noncarrier family controls on 3 app tasks (eg, 2-back β = −0.49 [95% CI, −0.72 to −0.25]; P &amp;lt; .001) but not a composite of traditional neuropsychological measures (β = −0.14 [95% CI, −0.42 to 0.14]; P = .32).Conclusions and RelevanceThe findings of this cohort study suggest that smartphones could offer a feasible, reliable, valid, and scalable solution for remote evaluations of FTLD and may improve early detection. Smartphone assessments should be considered as a complementary approach to traditional in-person trial designs. Future research should validate these results in diverse populations and evaluate the utility of these tests for longitudinal monitoring.
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
Saloner, Rowan , Staffaroni, Adam M. , Dammer, Eric B. , Johnson, Erik C. B. , Wise, Amy B. , Heuer, Hilary W. , Forsberg, Leah K. , Lago, Argentina Lario , Webb, Julia D, Kramer, Joel H. , Li, Jingyao , Sivasankaran, Rajeev , Seyfried, Nicholas T. , Yokoyama, Jennifer S. , Grinberg, Lea T. , Ljubenkov, Peter A. , Brushaber, Danielle , Considine, Ciaran , Day, Gregory S. , Faber, Kelley , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hales, Chadwick M. , Huey, Edward D. , Kornak, John , Lee, Suzee, Mendez, Mario F. , Miyagawa, Toji , Pascual, Belén , Paulson, Henry L. , Petrucelli, Leonard , Ramos, Eliana Marisa , Rascovsky, Katya, Savica, Rodolfo , Snyder, Allison , Sullivan, A. Campbell , Vandebergh, Marijne , Rosen, Howie, Boxer, Adam L. , Casaletto, Kaitlin B. , Staffaroni, Adam M , Hansson, Oskar , Sivasankaran, Rajeev , Yokoyama, Jennifer , Spina, Salvatore , Grinberg, Lea , VandeVrede, Lawren , Brushaber, Danielle , Day, Gregory S , Dickerson, Bradford Clark , Domoto-Reilly, Kimiko , Galasko, Douglas , Geschwind, Daniel , Ghoshal, Nupur , Honig, Lawrence S. , Hsiung, Gink-Yuek , Lapid, Maria I. , Litvan, Irene , Mendez, Mario , Pascual, Belen , Roberson, Erik , Snyder, Allison , Tartaglia, Maria Carmela , Vandebergh, Marijne , Boeve, Brad , Paulson, Henry L , Dammer, Eric B

Mayo Clinic

No container title available | March 28, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4103685/v1 | PMID 38585969 Get It

Abstract The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. We leveraged aptamer-based proteomics (> 4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations (C9orf72, GRN, MAPT) compared to 39 noncarrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN) and extracellular matrix (particularly in MAPT) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of 1) sporadic progressive supranuclear palsy-Richardson syndrome and 2) frontotemporal dementia spectrum syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. ‘Hub’ proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.
Music Therapy Intervention to Reduce Symptom Burden in Hospice Patients: A Descriptive Study
Estell, Madison, Whitford, Kevin J. , Ulrich, Angela M., Larsen, Brianna E. , Wood, Christina M., Bigelow, Maureen L., Dockter, Travis , Schoonover, Kimberly , Stelpflug, Amy J., Strand, Jacob J. , Walton, Monica P., Estell, Madison H, Wood, Christina, Dockter, Travis J, Schoonover, Kimberly L, Lapid, Maria I.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | March 19, 2024 | Volume: 42 | Issue: 1 | Pages: 102-111

10.1177/10499091241237991 | PMID 38501668 Get It

Background: Music therapy (MT) offers benefits of improved symptom relief and quality of life at the end of life, but its impact on hospice patients and caregivers needs more research. Objective: To assess the impact of MT intervention on symptom burden and well-being of hospice patients and caregivers. Methods: A total of 18 hospice patients, selected based on scores ≥4 on the revised Edmonton Symptom Assessment System (ESAS-r) items on pain, depression, anxiety, or well-being, participated in MT sessions provided by a board-certified music therapist. Over a period of 2-3 weeks, 3-4 MT sessions were conducted for each. Patient Quality of life (QOL) was assessed using the Linear Analogue Self-Assessment (LASA). Depression and anxiety were measured with the Patient Health Questionnaire-4 (PHQ-4). For the 7 caregivers enrolled, stress levels were measured using the Pearlin role overload measure and LASA. Results: Patients reported a reduction in symptom severity and emotional distress and an increase in QOL. All patients endorsed satisfaction with music therapy, describing it as particularly beneficial for stress relief, relaxation, spiritual support, emotional support, and well-being. Scores on overall QOL and stress were worse for caregivers. Conclusion: This study provides evidence that MT reduces symptom burden and enhances the quality of life for hospice patients. Hospice patients and their caregivers endorsed satisfaction with MT. Given the benefits observed, integrating MT into hospice care regimens could potentially improve patient and caregiver outcomes. Larger studies should be conducted to better assess the impact of MT in this population.
Developing and describing a typology of lucid episodes among people with Alzheimer's disease and related dementias
Griffin, Joan M. , Kim, Kyungmin , Finnie, Dawn M., Gaugler, Joseph E. , Batthyány, Alexander , Bangerter, Lauren R. , Biggar, Virginia , Frangiosa, Theresa, Griffin, Joan M , Gaugler, Joseph E , Lapid, Maria I. , Kim, Kyungmin

Mayo Clinic

Alzheimer's & Dementia | February 2, 2024 | Volume: 20 | Issue: 4 | Pages: 2434-2443

10.1002/alz.13667 | PMID 38305566 Get It

AbstractINTRODUCTIONThis study examined lucid episodes among people living with late‐stage Alzheimer's disease and related dementias (PLWD) and then developed a typology of these episodes to help characterize them.METHODSFamily caregivers of PLWD provided information about witnessed episodes, including proximity to death, cognitive status, duration, communication quality, and circumstances prior to lucid episodes on up to two episodes (caregiver N = 151; episode N = 279). Latent class analysis was used to classify and characterize empirically distinct clusters of lucid episodes.RESULTSFour lucid episode types were identified. The most common type occurred during visits with family and among PLWD who lived > 6 months after the episode. The least common type coincided with family visits and occurred within 7 days of the PLWD's death.DISCUSSIONFindings suggest that multiple types of lucid episodes exist; not all signal impending death; and some, but not all, are precipitated by external stimuli.